In a strategic attempt to solve the global antimicrobial resistance (AMR) challenge, AdjuTec Pharma AS, a Norwegian business developing antibiotic resistance breakers, has established a research collaboration with Venus Remedies Limited in India. Venus Remedies will do preclinical tests on AdjuTec Pharma's APC-148 platform technology, which is a new inhibitor that is meant to make antibiotics work again against bacteria that are resistant to multiple drugs.

AdjuTec Pharma's APC-148 technology targets and inhibits bacterial resistance processes, restoring antibiotic efficacy. The platform is currently in Phase 1 clinical studies and shows promise for reversing resistance in diseases that represent the greatest danger to global health. Venus Remedies Limited, a renowned expert in AMR research, will use its enormous library of clinical isolates from the GASAR study to assess APC-148's efficacy in combination with other antibiotics.

A Rising Global Threat: AMR by the Numbers

According to the World Health Organisation (WHO), AMR is a critical worldwide health concern that kills 1.3 million people each year and is expected to kill 39 million people in total by 2050 if not addressed. The economic toll is as frightening, with a potential 3.8% reduction in global GDP and an increase of 10 million fatalities per year by 2050. The World Health Organisation cautions that antibiotic resistance could turn common diseases and mild injuries lethal without immediate action.

India's AMR Crisis: A Critical Challenge

India is at the epicentre of the AMR epidemic, with an estimated 300,000 deaths attributed to it in 2019. Neonatal sepsis caused by multidrug-resistant bacteria continues to be a major contributor to infant mortality. A 2022 study published in The Lancet assigns 20% of the worldwide AMR burden to India, emphasising the critical need for novel therapies such as APC-148.

Venus Remedies Limited will conduct rigorous preclinical research to determine APC-148's ability to treat resistant bacterial strains found in India's healthcare system. The collaboration is consistent with the United Nations' 'One Health' paradigm, which calls for a coordinated, multisectoral approach to combating AMR in human, animal, and environmental health.

Shared commitment to innovation

AdjuTec Pharma's CEO, Jethro Holter, expressed excitement about the collaboration with Venus Remedies, a well-known Indian company, to develop more effective antibiotics to address the global AMR epidemic. This arrangement is perfectly aligned with our aim of collaborating with premier worldwide pharmaceutical partners to address the most clinically problematic resistant infections using our revolutionary technology."

Venus Remedies President Saransh Chaudhary stated, "We are pleased to collaborate with AdjuTec Pharma on the preclinical evaluation of APC-148." This research collaboration allows us to contribute our AMR experience to further scientific understanding of novel solutions in this space. Our collaboration demonstrates a common commitment to addressing the worldwide AMR threat through thorough, innovative research."

The collaboration between AdjuTec Pharma and Venus Remedies is an important and promising step in the battle against antimicrobial resistance. Considering that India has a higher than average rate of AMR-related deaths, finding effective antibiotic resistance breakers like APC-148 could be the key to making current antibiotics work again. While technology advancements are critical, tackling the systemic causes that contribute to AMR—such as antibiotic misuse, insufficient infection prevention, and a lack of public awareness—is as important. A comprehensive plan involving research, policy reforms, and public participation is required to keep AMR from becoming the primary cause of world mortality by 2050.